New study aims for Long-Term remission in Standard-Risk myeloma

NCT ID NCT06577025

Ongoing Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This study is for people newly diagnosed with a standard-risk form of multiple myeloma, a blood cancer. Researchers want to see if giving a sequence of advanced cell therapies (Cilta-cel, Tal-D, Tec-D) after initial chemotherapy can lead to a very deep and lasting remission, possibly with no detectable cancer cells for at least 2 years. The goal is to improve long-term outcomes and potentially achieve a state close to a cure, though ongoing monitoring will be needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

City of Hope

Duarte, California, 91010, United States
Fundacao Antonio Prudente A C Camargo Cancer Center

São Paulo, 01509 900, Brazil
Hosp Clinico Univ de Salamanca

Salamanca, 37007, Spain
Hosp. Univ. 12 de Octubre

Madrid, 28041, Spain
Hosp. Univ. Marques de Valdecilla

Santander, 39008, Spain
Instituto D Or de Pesquisa e Ensino

Salvador, 41253 190, Brazil
Levine Cancer Institute

Charlotte, North Carolina, 28204, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Peter MacCallum Cancer Centre

Melbourne, 3000, Australia
Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein

São Paulo, 05652 900, Brazil
The Alfred Hospital

Melbourne, 3004, Australia
Universitaetsklinikum Heidelberg

Heidelberg, 69120, Germany
Universitaetsklinikum Tuebingen

Tübingen, 72076, Germany
Universitatsklinikum Wurzburg

Würzburg, 97080, Germany
University of California San Francisco

San Francisco, California, 94143, United States
University of Iowa Hospital and Clinics

Iowa City, Iowa, 52242, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.